| Trial ID: | L0349 |
| Source ID: | NCT05090111
|
| Associated Drug: |
ALG-055009
|
| Title: |
A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: ALG-055009|Drug: Placebo
|
| Outcome Measures: |
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Maximum Plasma Concentration [Cmax]|Area under the concentration time curve [AUC]|Time to maximum plasma concentration [Tmax]|Half-life [t1/2]|Minimum Plasma Concentration [Cmin]|Change in lipid / lipoprotein levels from baseline through Day 28 in Multiple Dose in Subjects with Mild Hyperlipidemia
|
| Sponsor/Collaborators: |
Aligos Therapeutics
|
| Gender: |
All
|
| Age: |
18 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
152
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
December 1, 2021
|
| Completion Date: |
September 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
January 11, 2022
|
| Locations: |
Biotrial, Rennes, France
|
| URL: |
https://ClinicalTrials.gov/show/NCT05090111
|
